Literature DB >> 12184906

Esophageal variceal bleeding secondary to portal hypertension: endoscopic sclerotherapy as the first-step treatment.

Ebru Yesildag1, Haluk Emir, Gonca Tekant, Nuvit Sarimurat, Pervin Bozkurt, Yuksel Yeker, Osman Faruk Senyuz.   

Abstract

BACKGROUND: Variceal bleeding from the esophagus is an important cause of mortality and morbidity in children with portal hypertension (PHT). PATIENTS AND METHODS: A series of 69 PHT cases (41 intrahepatic, 28 extrahepatic) have been evaluated in our department since 1990. According to the Child-Pugh classification, 49 cases were in class A, 16 cases were in class B, and 4 cases were in class C at admission. In our protocol, endoscopic sclerotherapy is performed in all patients, and the diagnosis is achieved directly by diagnostic laparoscopy and fine-needle liver biopsy. The procedure is applied under general anesthesia, and 1% aethoxysclerol (polidocanol) is injected paravariceally and intravariceally with the use of a flexible endoscope.
RESULTS: The Sugiura procedure was performed in nine patients who presented with recurrent bleeding episodes despite the strict sclerotherapy protocol. Liver transplantation was performed in two patients who were in Child class C. The total mortality rate in this series was 7% (5/69).
CONCLUSION: Endoscopic sclerotherapy, as presented herein, decreases the need for additional surgical interventions in children with PHT.

Entities:  

Mesh:

Year:  2002        PMID: 12184906     DOI: 10.1089/10926420260188100

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  1 in total

1.  The collateral caval shunt as an alternative to classical shunt procedures in patients with recurrent duodenal varices and extrahepatic portal vein thrombosis.

Authors:  Hans Michael Hau; Peter Fellmer; Markus B Schoenberg; Moritz Schmelzle; Mehmet Haluk Morgul; Felix Krenzien; Georg Wiltberger; Albrecht Hoffmeister; Sven Jonas
Journal:  Eur J Med Res       Date:  2014-06-25       Impact factor: 2.175

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.